Comparing the current results to its competitors, Sight Sciences Inc reported Revenue increase in the 1 quarter 2026 by 11.02 % year on year. The sales growth was above Sight Sciences Inc 's competitors' average revenue growth of 9.18 %, achieved in the same quarter.
Sight Sciences Inc , slower than the average decrease reported by the company's competitors of -44.37 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -44.37 %
Company's competitiveness improved within Overall company, with revenue growth of 11.02 % and its market share increased to approx. 0.09 %. << More on SGHT Market Share.
*Market share is calculated based on total revenue.
August 1, 2024
Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance MENLO PARK, Calif., Aug. 01, 2024 Sight Sciences, Inc. (Nasdaq: SGHT), a pioneering eyecare technology company, has released its financial results for the second quarter ended June 30, 2024. The company is dedicated to developing and commercializing innovative interventional technologies that aim to elevate the standard of care in eye care. Alongside its financial reports, Sight Sciences also provided an update on its financial guidance for the full year 2024, further refining its expectations for growth based on recent market conditions and operational performance. Financial Performance OverviewIn...
May 28, 2024
Sight Sciences Announces Promising Results from The ROMEO Study: OMNI Shows Effective Reductions in Pressure and Medication Usage Across All Stages of GlaucomaIn an exciting development for glaucoma patients, Sight Sciences has recently announced the publication of a new analysis from The ROMEO Study, demonstrating significant reductions in intraocular pressure (IOP) and medication usage achieved through the use of their OMNI surgical system. The analysis, which was published in Clinical Ophthalmology, provides evidence that OMNI is just as effective at addressing advanced glaucoma as it is with mild and moderate cases.Glaucoma, often referred to as the silent thief of sight, is a chronic eye condition chara...
April 10, 2024
Sight Sciences, a leading medical technology company, has recently published a groundbreaking study demonstrating the efficacy of their OMNI Surgical System in treating glaucoma. The study, which evaluated over 100,000 glaucoma patient eyes, compared the outcomes of three commonly used Minimally Invasive Glaucoma Surgery (MIGS) technologies in combination with cataract surgery and cataract surgery alone. The results indicate that the OMNI Surgical System not only effectively lowers intraocular pressure (IOP), but also reduces the need for IOP reducing medications over a period of two years.The MIGS Study: Evaluating Treatment Options for Glaucoma PatientsGlaucoma, a chronic eye condition characterized by inc...
April 2, 2024
In a remarkable breakthrough for the field of ophthalmology, Sight Sciences showcased the remarkable results of their GEMINI Trial and the cross-over phase of the SAHARA RCT at the prestigious 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. This pivotal event marked the unveiling of the OMNI Surgical System s long-term efficacy in treating primary open-angle glaucoma, as well as the TearCare technology s potential as a primary treatment for dry eye disease. These groundbreaking advancements have the potential to revolutionize ophthalmic care and improve the quality of life for millions of patients worldwide.OMNI Surgical System: Revolutionizing Glaucoma TreatmentPrimary open-...
3M Company operates a diversified business model by offering innovative solutions across multiple segments, including healthcare, safety and industrial, transportation, and consumer goods. The company leverages its extensive portfolio of patents and deep customer relationships to drive product development and market responsiveness, focusing on delivering value across various industries.
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
Acme United Corp's business model involves the production and distribution of various consumer goods and personal protective equipment, catering to a wide range of industries.
Alcon Inc's business model revolves around providing advanced eye care products and services, including pharmaceuticals, surgical equipment, and vision care solutions.
Glaukos Corp is a medical technology company that specializes in developing and commercializing ophthalmic treatment solutions. Their business model revolves around providing innovative products for the surgical treatment of glaucoma and other eye disorders. Through research, development, and partnerships, Glaukos aims to improve patient outcomes by offering minimally invasive, cost-effective treatments.
Sources:
Sight Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sight Sciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
